Mirum Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIRM research report →
Companywww.mirumpharma.com
Mirum Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
- CEO
- Christopher Peetz
- IPO
- 2019
- Employees
- 334
- HQ
- Foster City, CA, US
Price Chart
Valuation
- Market Cap
- $4.87B
- P/E
- -7.14
- P/S
- 8.54
- P/B
- 23.53
- EV/EBITDA
- -126.93
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 81.36%
- Op Margin
- -12.31%
- Net Margin
- -140.24%
- ROE
- -289.33%
- ROIC
- -11.30%
Growth & Income
- Revenue
- $521.31M · 54.74%
- Net Income
- $-23,363,000 · 73.43%
- EPS
- $-0.47 · 74.59%
- Op Income
- $-22,136,000
- FCF YoY
- 488.01%
Performance & Tape
- 52W High
- $114.99
- 52W Low
- $42.89
- 50D MA
- $96.09
- 200D MA
- $82.84
- Beta
- 0.52
- Avg Volume
- 1.01M
Get TickerSpark's AI analysis on MIRM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Ramasastry Saira | other | 2,000 |
| May 15, 26 | Ramasastry Saira | sell | 2,000 |
| May 15, 26 | Ramasastry Saira | other | 2,000 |
| Apr 15, 26 | Ramasastry Saira | other | 2,000 |
| Apr 15, 26 | Ramasastry Saira | other | 2,000 |
| Apr 15, 26 | Ramasastry Saira | sell | 2,000 |
| Mar 15, 26 | BJERKHOLT ERIC | other | 13,334 |
| Mar 16, 26 | BJERKHOLT ERIC | sell | 7,287 |
| Mar 15, 26 | BJERKHOLT ERIC | other | 13,334 |
| Mar 15, 26 | Quan Joanne | other | 13,334 |
Our MIRM Coverage
We haven't published any research on MIRM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MIRM Report →